Search research articles
Contact Us
Filters
Showing results (501-510 of 555) with videos related to
Page
of 56
Sort By:
The Lancet. Oncology
|
May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
Isabelle Ray-Coquard, Paolo Giovanni Casali, Sabrina Croce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)
Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
ESMO Open
|
March 8, 2025
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial
A Vanzulli, R Vigorito, C Buonomenna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2020
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups
Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2023
Translational Aspects of Epithelioid Sarcoma: Current Consensus
Thomas G P Grünewald, Sophie Postel-Vinay, Robert T Nakayama, et al.
The Lancet Regional Health. Europe
|
February 22, 2024
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
Jean-Yves Blay, Paolo Casali, Isabelle Ray-Coquard, et al.
Molecular Cancer
|
August 9, 2023
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Javier Martin-Broto, Claudia Valverde, Nadia Hindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
David S Moura, Jesus M Lopez-Marti, Iva Benesova, et al.
JAMA Network Open
|
November 6, 2025
Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial
Sandro Pasquali, Paola Collini, Cleofe Romagosa, et al.
Page
of 56
Search research articles
Search
Showing results (501-510 of 555) with videos related to
Sort By:
Page
of 56
The Lancet. Oncology
|
May 14, 2017
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
Isabelle Ray-Coquard, Paolo Giovanni Casali, Sabrina Croce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)
Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
ESMO Open
|
March 8, 2025
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial
A Vanzulli, R Vigorito, C Buonomenna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2020
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups
Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 2, 2023
Translational Aspects of Epithelioid Sarcoma: Current Consensus
Thomas G P Grünewald, Sophie Postel-Vinay, Robert T Nakayama, et al.
The Lancet Regional Health. Europe
|
February 22, 2024
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
Jean-Yves Blay, Paolo Casali, Isabelle Ray-Coquard, et al.
Molecular Cancer
|
August 9, 2023
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Javier Martin-Broto, Claudia Valverde, Nadia Hindi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
David S Moura, Jesus M Lopez-Marti, Iva Benesova, et al.
JAMA Network Open
|
November 6, 2025
Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial
Sandro Pasquali, Paola Collini, Cleofe Romagosa, et al.
Page
of 56